These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10930993)

  • 1. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia.
    Wuchter C; Karawajew L; Ruppert V; Schrappe M; Harbott J; Ratei R; Dörken B; Ludwig WD
    Br J Haematol; 2000 Jul; 110(1):154-60. PubMed ID: 10930993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
    Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
    Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.
    Aref S; Salama O; Al-Tonbary Y; Mansour A
    Hematology; 2004 Apr; 9(2):113-21. PubMed ID: 15203866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells.
    Karawajew L; Wuchter C; Ruppert V; Drexler H; Gruss HJ; Dörken B; Ludwig WD
    Leukemia; 1997 Aug; 11(8):1245-52. PubMed ID: 9264377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis and bcl-2 expression in acute lymphoblastic leukaemia and non-Hodgkin's lymphoma in children.
    Pituch-Noworolska A; Hajto B; Balwierz W; Klus K
    Haematologia (Budap); 2001; 31(3):191-207. PubMed ID: 11855781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 99mTc tetrofosmin scintigraphy in acute leukaemia: the relationship between marrow uptake of tetrofosmin and P-glycoprotein and chemotherapy response.
    Sükan A; Yapar Z; SAhin B; Kara O; Fuat Yapar A; CEtiner S; Kibar M
    Nucl Med Commun; 2004 Aug; 25(8):777-85. PubMed ID: 15266171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia.
    Karawajew L; Ruppert V; Wuchter C; Kösser A; Schrappe M; Dörken B; Ludwig WD
    Blood; 2000 Jul; 96(1):297-306. PubMed ID: 10891465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients.
    Baryshnikov AYu ; Polosukhina ER; Tupitsin NN; Gavrikova NV; Andreeva LYu ; Zabotina TN; Mayakova SA; Kurmashov VI; Syrkin AB; Kadagidze ZG; Blochin DYu ; Shishkin YuV
    Adv Exp Med Biol; 1999; 457():251-8. PubMed ID: 10500800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
    Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
    Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of CD95, Active Caspase-3, and Bcl-2 Expression in Adult Patients with De Novo Acute Lymphoblastic Leukemia.
    Montiel-Cervantes LA; Reyes-Maldonado E; Garcia-Chavez J; Hernandez-Caballero A; Molina-Aguilar R; Garcia-Ruiz Esparza MA; Vela-Ojeda J
    Arch Med Res; 2018 Jan; 49(1):44-50. PubMed ID: 29680307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL.
    Kanerva J; Tiirikainen M; Mäkipernaa A; Riikonen P; Möttönen M; Salmi TT; Krusius T; Saarinen-Pihkala UM
    Pediatr Hematol Oncol; 1998; 15(1):11-21. PubMed ID: 9509502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia.
    Wuchter C; Ruppert V; Schrappe M; Dörken B; Ludwig WD; Karawajew L
    Blood; 2002 Jun; 99(11):4109-15. PubMed ID: 12010814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
    Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
    Zhou M; Gu L; Yeager AM; Findley HW
    Leukemia; 1998 Nov; 12(11):1756-63. PubMed ID: 9823951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia.
    Avgeris M; Stamati L; Kontos CK; Piatopoulou D; Marmarinos A; Xagorari M; Baka M; Doganis D; Anastasiou T; Kosmidis H; Gourgiotis D; Scorilas A
    Clin Chem Lab Med; 2018 Nov; 56(12):2104-2118. PubMed ID: 30016275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
    Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
    Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia.
    Beltinger C; Böhler T; Karawajew L; Ludwig WD; Schrappe M; Debatin KM
    Br J Haematol; 1998 Aug; 102(3):722-8. PubMed ID: 9722299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.